Quantcast
Home > Quotes > VIVE

Viveve Medical, Inc. Common Stock (VIVE) Quote & Summary Data

VIVE 
$3.575
*  
0.235
6.17%
Get VIVE Alerts
*Delayed - data as of Jun. 19, 2018  -  Find a broker to begin trading VIVE now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    VIVE Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
9
Today's High / Low
$ 4.15 / $ 3.37
Share Volume
2,094,892
50 Day Avg. Daily Volume
554,041
Previous Close
$ 3.81
52 Week High / Low
$ 8.75 / $ 1.60
Market Cap
111,788,062
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.06

Intraday Chart

Shares Traded

Share Volume:
2,094,892
50 Day Avg. Daily Volume:
554,041

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.06

Trading Range

The current last sale of $3.575 is 123.44% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 4.15 $ 8.75
 Low: $ 3.37 $ 1.60

Company Description (as filed with the SEC)

Viveve designs, develops, manufactures and markets a platform medical technology, which we refer to as Cryogen-cooled Monopolar RadioFrequency, or CMRF. Our proprietary CMRF technology is delivered through a radiofrequency generator, handpiece and treatment tip, that collectively, we refer to as the Viveve System®. The Viveve System is currently being marketed around the world (outside of the United States) for the non-invasive treatment of various post-partum conditions including vaginal introital laxity, for improved sexual function, and for vaginal rejuvenation, depending on the relevant country-specific clearance or approval, that we refer to as the Geneveve(TM) treatment.  ... More ...  

Risk Grade

Where does VIVE fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 4.15
Open Date:
Jun. 19, 2018
Close Price:
$ 3.81
Close Date:
Jun. 19, 2018

Consensus Recommendation

Analyst Info